Ersbøll, Annette Kjær https://orcid.org/0000-0002-9407-3387
Huang, Zhiping https://orcid.org/0009-0006-6196-0277
Hill, Deanna D.
Hede, Simone Møller https://orcid.org/0000-0003-2074-7921
Andersen, Vibeke https://orcid.org/0000-0002-0127-2863
Bolin, Kristian
Kristensen, Marie Skov https://orcid.org/0000-0002-8066-8937
Esslinger, Suzan https://orcid.org/0000-0003-1052-058X
Hansen, Frida Richter https://orcid.org/0000-0002-4729-2683
Hertervig, Erik
Kallio, Lila
Kjærulff, Thora Majlund https://orcid.org/0000-0002-3314-6570
Kloster, Stine https://orcid.org/0000-0002-6142-8305
Krumme, Alexis https://orcid.org/0000-0001-9633-861X
Lewis, James D. https://orcid.org/0000-0003-3107-3862
Mehkri, Laila
Qvist, Niels
Thygesen, Lau Caspar https://orcid.org/0000-0001-8375-5211
Weinstein, Cindy https://orcid.org/0000-0003-4229-4644
Green, Anders https://orcid.org/0000-0002-5059-3655
Funding for this research was provided by:
Merck
University of Southern Denmark
Article History
Accepted: 19 January 2025
First Online: 6 February 2025
Declarations
:
: Open access funding provided by University of Southern Denmark. This post-authorization safety study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and Janssen Research & Development, LLC, Spring House, PA, USA. MedEngine DK ApS (formerly the Institute of Applied Economics and Health Research ApS, ApHER), an independent research institute, was contracted by Merck Sharp & Dohme LLC to conduct the study.
: JL has consulted or served on an advisory board for AbbVie, Amgen, Arena Pharmaceuticals, Bridge Biotherapeutics, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Entasis Therapeutics, Galapagos, Gilead, Janssen Pharmaceuticals, Samsung Bioepis, Merck, Nestle Health Science, UCB, Pfizer, Protagonist Therapeutics, Sanofi, and Scipher Medicine; has received research funding from Nestle Health Science, Takeda, Janssen Pharmaceuticals, and AbbVie; has received educational grants from Takeda and Janssen; and has received in-kind support from Eli Lilly and Company. VA is member of the Merck advisory board and has consulted for Janssen. LM, SMH, and LK were employees at ApHER/MedEngine while the study was conducted. ZH, DDH, and CW are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may hold stock and/or stock options in Merck & Co., Inc., Rahway, NJ, USA. SE and AK were employees at Janssen while the study was conducted. KB and AG were responsible for the study in Sweden as consultants for ApHER/MedEngine. AKE, LCT, TMK, MSK, SK, FRH, NQ, and EH have no conflicts of interest to declare.
: Register-based micro-level data sharing is not permitted. The researchers (AKE and AG) have access to data at secure servers at the Danish Health Data Authority and at secure local servers.
: Different ethical approvals are needed in Denmark and Sweden [, ]. In Denmark, register-based studies do not need ethical approval []. The study was approved by the Research and Innovation Organisation at University of Southern Denmark (reference number: 10.186). The Swedish Ethical Review Authority approved the initial study protocol (reference 2019-04411) and amendments (reference 2020-00038). In Denmark, a minimum of five observations is needed to present results because of privacy regulations. Consequently, numbers less than five are masked as “<5” for results. So that the masked number cannot be calculated, further results have been masked and indicated as not permissible.
: Not applicable.
: Not applicable.
: Not applicable.
: AKE: conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing – original draft, writing – review and editing, visualization, and project administration. LCT: conceptualization, methodology, software, investigation, resources, data curation, writing – review and editing, and supervision. TMK: conceptualization, methodology, software, investigation, resources, data curation, and writing – review and editing. MSK: conceptualization, methodology, software, investigation, resources, data curation, and writing – review and editing. SK: methodology, software, resources, writing – review and editing, and visualization. FRH: methodology, software, resources, and writing – review and editing. NQ: conceptualization, investigation, writing – review and editing, visualization, and supervision. VA: conceptualization, investigation, writing – review and editing, visualization, and supervision. EH: conceptualization, investigation, writing – review and editing, visualization, and supervision. JL: conceptualization, investigation, writing – review and editing, and visualization. LM: software, formal analysis, investigation, resources, data curation, writing – review and editing, and project administration. SMH: conceptualization, investigation, writing – review and editing, and project administration. LK investigation, resources, writing – review and editing, visualization, and project administration. SE: conceptualization, investigation, and writing – review and editing. AK: conceptualization, investigation, and writing – review and editing. CW: conceptualization, methodology, investigation, writing – review and editing, and supervision. DDH: conceptualization, investigation, methodology, writing – review and editing, supervision, and project administration. ZH: conceptualization, methodology, validation, investigation, writing – review and editing, supervision, and project administration. KB: conceptualization, resources, data curation, and writing – review and editing. AG: conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing – review and editing, visualization, supervision, and project administration. All authors read and approved the final manuscript.